GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Basic Sciences/Stromal Stiffness and Immune Evasion in Pancreatic Cancer

Stromal Stiffness and Immune Evasion in Pancreatic Cancer

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated August 1, 2025

Quick Answer

Stromal stiffness plays a critical role in promoting immune evasion in pancreatic ductal adenocarcinoma (PDAC). The study highlights a mechanistic link between the tumor microenvironment, particularly stromal stiffness, and immune resistance through an epigenetic-metabolic pathway.


Stromal stiffness plays a critical role in promoting immune evasion in pancreatic ductal adenocarcinoma (PDAC). The study highlights a mechanistic link between the tumor microenvironment, particularly stromal stiffness, and immune resistance through an epigenetic-metabolic pathway.

### Key Findings:

1. **Role of IGF2BP2 in Immune Evasion**:

  • IGF2BP2, an m6A RNA-binding protein, was identified as a mediator of immune evasion in PDAC.
  • It stabilizes the transcripts of **SGMS2**, an enzyme involved in sphingomyelin synthesis, which is crucial for immune resistance.

2. **Mechanism of Immune Evasion**:

  • SGMS2 promotes the synthesis of sphingomyelin, a lipid that enhances the localization of **PD-L1** in lipid rafts.
  • PD-L1 in lipid rafts suppresses T-cell infiltration and activity, enabling the tumor to evade immune detection and destruction.

3. **Impact of Stromal Stiffness**:

  • The stiff extracellular matrix (ECM) in the tumor microenvironment prevents the degradation of IGF2BP2, leading to its upregulation.
  • This links stromal stiffness to increased IGF2BP2 activity, enhanced SGMS2 expression, and subsequent immune suppression.

4. **Therapeutic Implications**:

  • Dual inhibition of IGF2BP2 and SGMS2 was shown to reverse immune evasion in preclinical models.
  • This approach restored T-cell infiltration and activity, improved cytokine production, and prolonged survival in animal models of PDAC.

### Broader Significance:

The study uncovers a **stiffness-driven epigenetic-metabolic pathway** that underpins immune escape in pancreatic cancer. It provides insights into how the physical properties of the tumor microenvironment contribute to immune resistance, offering novel therapeutic targets. Targeting IGF2BP2 and SGMS2 could enhance the efficacy of immunotherapy in PDAC, a cancer type notoriously resistant to immune-based treatments.

This research emphasizes the importance of addressing not only the biological but also the mechanical aspects of the tumor microenvironment to combat immune evasion in pancreatic cancer.

Related Q&A

ARID1A Loss Drives ICC Development: Hepatology | June 2026

Introduction: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary liver cancer with poor prognosis and limited treatment options. While ICC has traditionally been considered a malignancy of biliary epithelial cells, increasing evidence suggests that hepatocytes can...

Blocking Succinate–GPR91 Signaling in MASH: Hepatology | April 2026

Introduction: Liver fibrosis is the key determinant of long-term outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Activated hepatic stellate cells (HSCs) drive fibrogenesis, but effective antifibrotic therapies remain unavailable. This study investigated whether blocking the succinate–GPR91...

THRSP–MIF Signaling Drives MASH Progression: Hepatology | April 2026

Introduction: The progression from metabolic dysfunction-associated fatty liver (MAFL) to metabolic dysfunction-associated steatohepatitis (MASH) is driven by complex interactions between hepatocytes and immune cells. This study identifies a novel spatial mechanism in the periportal (PP)...

Butyrate and Butyrate-Producing Bacteria in CKM: Antioxidants | July 2026

Introduction: Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the close interaction between obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. This review highlights the emerging role of the gut microbiome, particularly butyrate-producing bacteria, as a central...

CK7, CK20, and CDX2 Refine Prognosis in Small Intestinal Adenocarcinoma: Annals of Oncology | 2026

• Small intestinal adenocarcinoma (SIA) is a rare gastrointestinal cancer with limited disease-specific prognostic biomarkers and generally poor outcomes. • This nationwide Dutch population-based study evaluated whether three routinely available immunohistochemical markers—CK7, CK20, and CDX2—have...

Fatty Liver Drives Hyperglycemia Through Liver–Gut Signaling : Cell Metab | Jun 2026

Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to insulin resistance and type 2 diabetes, with the liver traditionally viewed as a key regulator of blood glucose through hepatic glucose production. However, emerging...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer